

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TIAN YUAN HEALTHCARE

天元医疗

CHINA TIAN YUAN HEALTHCARE GROUP LIMITED

中國天元醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 557)

**(1) RESIGNATION OF EXECUTIVE DIRECTOR;
(2) CHANGE OF CHIEF EXECUTIVE OFFICER;
(3) CHANGE OF AUTHORISED REPRESENTATIVE; AND
(4) CHANGE IN COMPOSITION OF REMUNERATION COMMITTEE**

The Board announces that, with effect from 19 January 2022:

- (1) Ms. Zhang Xian has resigned as the executive Director, the chief executive officer, the member of the Remuneration Committee and the Authorised Representative; and
- (2) Ms. Dong Wei has been appointed as the chief executive officer, the member of the Remuneration Committee and the Authorised Representative.

**RESIGNATION OF MS. ZHANG XIAN AS THE EXECUTIVE DIRECTOR, THE CEO,
THE AUTHORISED REPRESENTATIVE AND THE MEMBER OF THE REMUNERATION
COMMITTEE**

The board (the “**Board**”) of directors (the “**Directors**”) of China Tian Yuan Healthcare Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Ms. Zhang Xian (“**Ms. Zhang**”) has tendered her resignation as the executive Director, the chief executive officer (the “**CEO**”) and an authorised representative (the “**Authorised Representative**”) of the Company under Rule 3.05 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), and the member of the remuneration committee of the Board (the “**Remuneration Committee**”) with effect from 19 January 2022 in order to devote more time to her personal endeavors.

Ms. Zhang has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

APPOINTMENT OF MS. DONG WEI AS THE CEO, THE AUTHORISED REPRESENTATIVE AND THE MEMBER OF REMUNERATION COMMITTEE

The Board is pleased to announce that Ms. Dong Wei (“**Ms. Dong**”), the executive Director of the Company, has been appointed as the CEO, the Authorised Representative and the member of Remuneration Committee of the Company with effect from 19 January 2022.

Ms. Dong, aged 28, obtained a bachelor degree in Marketing from Anglia Ruskin University, United Kingdom in 2016. Ms. Dong joined the Group in July 2021 and was appointed as the executive Director of the Company on 30 December 2021. Before her appointment as the executive Director of the Company, she has been serving as the director assistant of the Company, during which she has been responsible for assisting the directors with planning and implementing strategies. Ms. Dong served as assistant manager of human resources department of China Huarong Asset Management Co., Ltd., which is listed on the Hong Kong Stock Exchange (Stock Code: 2799) from June 2017 to February 2019. From February 2019 to July 2021, Ms. Dong served as administrative manager of international trade department in Beijing Tianyuan Manganese Industry Co., Ltd.* (北京天元錳業有限公司). Ms. Dong is a daughter of Mr. Jia Tianjiang (being the controlling shareholder of the Company).

Save as disclosed above, Ms. Dong (i) does not hold any other position within the Group; (ii) has not held any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) does not have any relationships with any directors, senior management or substantial or controlling shareholders of the Company. As at the date of this announcement, so far as the Directors are aware of, Ms. Dong is not interested or deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the “**SFO**”).

Ms. Dong has entered into a service contract with the Company under which she agreed to act as an executive Director of the Company for a term of two years commencing from 30 December 2021. Ms. Dong shall hold office of the executive Director until the next following general meeting of the Company at which she shall be eligible for re-election in accordance with the articles of association of the Company (the “**Articles**”). Such appointment is also subject to retirement by rotation at least once every three years in accordance with the Articles. Ms. Dong and the Company will not enter into a new service contract for her appointment as the CEO, the Authorised Representative and the member of the Remuneration Committee. Ms. Dong is entitled to a fixed sum salary of RMB600,000 per annum and a discretionary bonus as may be approved by the Board. Her emoluments were recommended by the Remuneration Committee and determined by the Board with reference to, among others, her duties and responsibilities with the Company, her experience and the prevailing market conditions. No additional remuneration will be paid to Ms. Dong for her appointment as the CEO, the Authorised Representative and the member of the Remuneration Committee.

Save as disclosed above, there is no other information relating to Ms. Dong which needs to be disclosed pursuant to any of the requirements of paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules. Further, there are no other matters which need to be brought to the attention of the shareholders of the Company

By order of the board
China Tian Yuan Healthcare Group Limited
Wang Huabing
Executive Director

Hong Kong, 20 January 2022

As at the date of this announcement, the Board is composed of seven directors of which Mr. Wang Huabing (chairman) and Ms. Dong Wei are the executive directors, Ms. He Mei and Mr. Zhou Yuan are the non-executive directors and Mr. Hu Baihe, Mr. Yuen Kwok Kuen and Mr. Guo Jingbin are the independent non-executive directors.

* *For identification purpose only*